ALX Oncology Files 8-K for Financials
Ticker: ALXO · Form: 8-K · Filed: Mar 6, 2025 · CIK: 1810182
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: ALXO
TL;DR
ALXO filed an 8-K for financial reporting, no major news.
AI Summary
ALX Oncology Holdings Inc. filed an 8-K on March 6, 2025, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not appear to contain specific financial figures or operational updates beyond the procedural nature of the report.
Why It Matters
This filing indicates ALX Oncology is adhering to its reporting obligations, providing a snapshot of its financial status and operational disclosures to investors.
Risk Assessment
Risk Level: low — This is a routine filing for financial reporting and does not appear to contain any new material information that would immediately impact the company's risk profile.
Key Players & Entities
- ALX Oncology Holdings Inc. (company) — Registrant
- 0000950170-25-034574 (document_id) — Accession Number
- 20250306 (date) — Filing Date
- 323 Allerton Avenue, South San Francisco, California 94080 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by ALX Oncology Holdings Inc.?
The primary purpose of this 8-K filing is to report on the company's results of operations and financial condition, and to file financial statements and exhibits.
On what date was this 8-K filing submitted?
This 8-K filing was submitted on March 6, 2025.
What is the Commission File Number for ALX Oncology Holdings Inc.?
The Commission File Number for ALX Oncology Holdings Inc. is 001-39386.
Where are ALX Oncology Holdings Inc.'s principal executive offices located?
ALX Oncology Holdings Inc.'s principal executive offices are located at 323 Allerton Avenue, South San Francisco, California 94080.
Does this filing indicate any specific new developments or material events for ALX Oncology?
Based on the provided text, this filing appears to be a routine report on results of operations and financial condition, and does not explicitly detail any new material events beyond the standard reporting requirements.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 6, 2025 regarding ALX ONCOLOGY HOLDINGS INC (ALXO).